Education
About Us
Working with TipRanks
Follow Us
Republic Healthcare Limited (HK:8357)
:8357
RESEARCH TOOLSreports
Top Page
Republic Healthcare Limited
(8357)
Rating:60Neutral
Price Target:―
Republic Healthcare Limited (8357) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$61.78M
Dividend YieldN/A
Average Volume (3M)100.83K
Price to Earnings (P/E)―
Beta (1Y)0.15
Revenue Growth-13.38%
EPS Growth78.75%
CountryHK
Employees34
SectorHealthcare
Sector Strength42
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding624,000,000
10 Day Avg. Volume82,000
30 Day Avg. Volume100,833
Financial Highlights & Ratios
PEG Ratio-0.62
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio165.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Republic Healthcare Limited Business Overview & Revenue Model
Company DescriptionRepublic Healthcare Limited, a primary healthcare services company, provides consultation, medical investigation, and treatment services in Singapore. The company offers various treatment solutions for common medical conditions and focuses on sexual health and infectious diseases. It also provides treatment solutions for common skin conditions and basic medical aesthetics services. The company operates nine clinics under the Dr. Tan & Partners brand name; and one clinic under the S Aesthetics brand name. Republic Healthcare Limited was founded in 2010 and is headquartered in Singapore.
How the Company Makes MoneyRepublic Healthcare Limited generates revenue primarily through its provision of medical services. The company earns money by charging patients for consultations with general practitioners and specialists, as well as for various medical procedures and treatments offered at its facilities. Additionally, the company may have partnerships with healthcare providers and insurance companies, which can facilitate patient referrals and reimbursements, thus contributing to its earnings. Revenue can also be derived from ancillary services, such as diagnostic tests and preventive healthcare programs. These diversified revenue streams enable the company to maintain a stable financial performance.
Republic Healthcare Limited Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 9.23M | 10.00M | 9.04M | 13.37M | 13.72M | Gross Profit |
| 2.26M | 6.83M | 5.97M | 9.13M | 9.83M | EBIT |
| 1.70M | 0.00 | -1.08M | -930.21K | -10.88K | EBITDA |
| -188.79K | 29.34K | -387.88K | 962.89K | 1.43M | Net Income Common Stockholders |
| -178.16K | -855.12K | -1.47M | -997.93K | 65.90K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 11.52M | 11.93M | 11.83M | 14.14M | 13.07M | Total Assets |
| 14.48M | 15.64M | 16.42M | 19.27M | 19.34M | Total Debt |
| 858.22K | 961.16K | 810.47K | 1.55M | 2.76M | Net Debt |
| -10.51M | -10.97M | -10.02M | -11.60M | -10.31M | Total Liabilities |
| 1.93M | 2.89M | 2.30M | 3.67M | 6.09M | Stockholders Equity |
| 12.55M | 12.75M | 14.12M | 15.59M | 13.26M |
| Cash Flow | Free Cash Flow | |||
| 51.27K | 806.24K | -1.16M | -1.13M | 232.36K | Operating Cash Flow |
| 125.07K | 899.91K | -734.46K | -510.07K | 771.30K | Investing Cash Flow |
| -93.94K | 831.49K | -987.23K | -1.56M | 7.62M | Financing Cash Flow |
| -531.65K | -587.62K | -689.73K | 2.28M | -1.36M |
Republic Healthcare Limited Technical Analysis
Positive
0.09
Price Trends
0.08
Positive
0.07
Positive
0.07
Positive
Market Momentum
<0.01
Negative
67.47
Neutral
64.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8357, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.09, above the 50-day MA of 0.08, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 67.47 is Neutral, neither overbought nor oversold. The STOCH value of 64.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8357.
Republic Healthcare Limited Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$61.78M | ― | -1.41% | ― | -13.38% | 78.75% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
51 Neutral | HK$124.00M | ― | -18.22% | ― | -56.16% | 62.50% | |
45 Neutral | HK$103.03M | ― | -12.06% | ― | 4.62% | -60.86% | |
44 Neutral | HK$22.09M | 114.12 | 0.88% | ― | 8.34% | ― |
* Healthcare Sector Average
Performance Comparison
HK:8357
Republic Healthcare Limited
0.10
>-0.01
-9.09%
HK:8267
Linekong Interactive Group Co., Ltd.
0.28
-0.13
-31.71%
HK:8186
M-Resources Group Limited
0.19
-1.61
-89.44%
HK:8143
Good Fellow Healthcare Holdings Limited
0.11
-0.05
-31.25%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.